TRACERS

IMAGING TRACERS

We provide our clients with highest quality radiopharmaceuticals, reliably delivered with care. We take pride in our record of having a 99% cyclotron uptime, allowing us to successfully deliver more than 400,000 doses annually, servicing imaging centers from coast-to-coast.

F18-Fludeoxyglucose

18F-FDG is indicated for positron emission tomography (PET) imaging in the following settings:

Oncology: For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer.

Cardiology: For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging.

Neurology: For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures.

Package Insert:  F18-Fludeoxyglucose is an approved product with the FDA, we follow 21 CFR Part 212, USP 797, and Board of Pharmacy regulations, and that we have established an effective quality and sterility assurance systems in place.

F18-Sodium Fluoride

F18-NaF is a radioactive diagnostic agent for positron emission tomography (PET) indicated for imaging of bone to define areas of altered osteogenic activity.

Package Insert:  F18-NaF is an approved product with the FDA, we follow 21 CFR Part 212, USP 797, and Board of Pharmacy regulations, and that we have established an effective quality and sterility assurance systems in place.

N13-Ammonia

N13-Ammonia is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.

Package Insert:  N13-Ammonia is an approved product with the FDA, we follow 21 CFR Part 212, USP 797, and Board of Pharmacy regulations, and that we have established an effective quality and sterility assurance systems in place.

Neuraceq™

Neuraceq™ is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline.

NETSPOT

NETSPOT, after radiolabeling with Ga 68, is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.

DetectNetTM

Detectnet is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients.

FIND A RADIOPHARMACY LOCATION

Dedicated to providing reliable, high quality products and cutting-edge technologies